NO120035B - - Google Patents
Download PDFInfo
- Publication number
- NO120035B NO120035B NO246169A NO246169A NO120035B NO 120035 B NO120035 B NO 120035B NO 246169 A NO246169 A NO 246169A NO 246169 A NO246169 A NO 246169A NO 120035 B NO120035 B NO 120035B
- Authority
- NO
- Norway
- Prior art keywords
- ethanol
- semicarbazide
- propanone
- imidazolyl
- nitro
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 6
- 238000009835 boiling Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 4
- -1 Histomonacids Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ZPGYOXBQOZVFQY-UHFFFAOYSA-N 1-(2-chloroethoxy)-3-(2-nitroimidazol-1-yl)propan-2-one Chemical compound [N+](=O)([O-])C=1N(C=CN1)CC(COCCCl)=O ZPGYOXBQOZVFQY-UHFFFAOYSA-N 0.000 description 1
- FPCFEEMMMCHLBI-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)propan-2-one Chemical compound CC(=O)CN1C=CN=C1[N+]([O-])=O FPCFEEMMMCHLBI-UHFFFAOYSA-N 0.000 description 1
- VQSYAQVEKOTYCZ-UHFFFAOYSA-N 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-one Chemical compound COCC(=O)CN1C=CN=C1[N+]([O-])=O VQSYAQVEKOTYCZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000948220 Histomonas meleagridis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241001058196 Tritrichomonas foetus Species 0.000 description 1
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
- 241000223107 Trypanosoma congolense Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002690 trypanocidal agent Substances 0.000 description 1
- 230000000654 trypanocidal effect Effects 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Fremgangsmåte for fremstilling av nye, terapeutisk
aktive imidazolderivater.
Oppfinnelsen vedrbrer fremstillingen av nye, terapeutisk aktive imidazolderivater med den generelle formel
hvor R^ betyr hydrogen, lavere alkoksy eller halogen-lavere-alkoksy. Forbindelsene med formel I fremstilles ifolge oppfinnelsen ved at man omsetter et keton med den generelle formel
hvor R-^ har foran angitte betydning,
med semikarbazid eller et salt av semikarbazid.
Denne omsetning til semikarbazonene med formel I finner hensiktsmessig sted i nærvær av et alkaliacetat, f.eks. natriumacetat-trihydrat, i et inert organisk opplosningsmiddel, som en lavere alkanol, f.eks. metanol eller .etanol, ved oket temperatur, f.eks. ved en temperatur mellom værelse-temperatur og kokepunktet av reaksjonsblandingen.
Forbindelsene med formel I og deres farmakologisk aksepterbare syreaddisjonssalter kan anvendes som antimikrobielle midler, spesielt mot bakterier, sopp, patogen gjær og protozoer, f.eks. mot Trichomonas vaginalis, Trichomonas foetus, Histomonas meleagridis, Endamoeba histolytica, Trypanosomer, f.eks. T. cruzi, T. rhodesiense, T. congolense. Forbindelsene med formel I kan på tilsvarende måte finne anvendelse som Germicider, Trichomonacider, Histomonacider, Trypanocider eller som midler til bekjempelse av gjærinfeksjoner.
For behandlingen av infeksjonssykdommer, som Trichomoniasis, Trypanosomiasis eller Histomoniasis kan forbindelsene ifolge oppfinnelsen anvendes oralt, parenteralt eller topisk. De kan overfores til de vanlige farmasoytiske anvendelsesformer, f.eks. ved blanding med organiske eller uorganiske bæremateri-aler, som vann, gelatin, laktose, stivelse, magnesiumstearat, vegetabilske oljer, gummi arabicum, polyalkylenglykoler, vaselin. De farmasoytiske preparatene kan foreligge i form av tabletter, dragéer, suppositorier, kapsler, salver eller i flytende form, f.eks. som opplbsninger, suspensjoner eller emulsjoner. De kan også enda inneholde hjelpestoffer, som konserverings-, stabiliserings-, fuktnings- eller emulgermiddel eller også salter til forandring av det osmo-tiske trykk. De kan også enda inneholde andre terapeutisk verdifulle stoffer. For den orale anvendelse kommer f.eks.
en dosering på ca. 10 til ca. 100 mg/kg kroppsvekt alt efter arten og individuelle forhold, på tale.
Syreaddisjonssalter kan oppnås ved omsetning med uorganiske syrer, som saltsyre, bromhydrogensyre, svovelsyre, eller med organiske syrer, som oksalsyre, eddiksyre, melkesyre, vinsyre.
I de efterfdlgende eksempler er temperaturene angitt i Celsius-grader .
EKSEMPEL 1
9,0b g l-(2-nitro-l-imidazolyl)-2-propanon opploses i 90 ml varm etanol og opplosningen tilsettes 90 ml destillert vann. Så tilsetter man under roring 9,05 g semikarbazid-hydroklorid og så 13,6 g natriumacetat-trihydrat og rorer inntil alt er opplost. Derpå oppvarmes opplosningen. Ved 45° danner krystaller seg. Blandingen holdes 15 minutter under roring nær ved kokning og avkjoles så. Nålene som danner seg samles, vaskes [med l-^O/etanol (1:1)] og torkes, smeltepunkt 222 - 223° (spaltning). Efter omkrystallisasjon fra kokende etanol smelter det således erholdte 1-(2-nitro-l-imidazolyl)-2-propanon-semikarbazon ved 224 - 225° (spaltning), ^^ax"0^ 310 mu; e = 4500.
EKSEMPEL 2
Til en opplosning av 0,40 g 1-(2-nitro-l-imidazolyl)-3-metoksy-2-propanon i 5 ml etanol tilsetter man 5 ml vann.
Så tilsetter man 0,40 g semikarbazid-hydroklorid og så 0,60 g natriumacetat-trihydrat og rbrer inntil alt er opplost. Opplosningen oppvarmes 15 minutter nesten inntil kokning
(det danner seg derved ingen faste stoffer) og avkjoles så. Den faste substans som danner seg filtreres og vaskes med 3
ml og så med 2 ml etanol/F^O (1:1), så tbrkes den. Smeltepunkt 181 - 183° (spaltning). Efter omkrystallisasjon fra kokende etanol (35 ml) oppnår man 1-(2-nitro-l-imidazolyl)-3-metoksy-2-propanon-semikarbazon med smeltepunkt 186 - 187°
(spaltning). X^no1 314 mu; £ = 7000.
EKSEMPEL 3
Til en opplosning av 0,90 g 1-(2-nitro-l-imidazolyl)-3-(2-kloretoksy)-2-propanon i 10 ml etanol tilsetter man 10 ml vann. Så tilsetter man 0,90 g semikarbazid-hydroklorid og. 1,35 g natriumacetat-trihydrat og rbrer inntil alt er opplost. Efter opparbeidelsen oppnår man 1-(2-nitro-l-imidazolyl)-3-(2-kloretoksy)-2-propanon-semikarbazon i form av farvelbse fine nåler med smeltepunkt 156,5 - 157°. ^^g^01 316 mu;
E = 7000
Claims (1)
- Fremgangsmåte for fremstilling av nye, terapeutisk aktive imidazolderivater med den generelle formelhvor R^ betyr hydrogen, lavere alkoksy eller halogen- lavere-alkoksy, karakterisert ved at man omsetter et keton med den aenerelle formel 0 hvor R-^ har foran angitte betydning, med semikarbazid eller et salt av semikarbazid. '
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO246169A NO120035B (no) | 1966-06-10 | 1969-06-13 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55658566A | 1966-06-10 | 1966-06-10 | |
| NO168540A NO118921B (no) | 1966-06-10 | 1967-06-09 | |
| US84007769A | 1969-04-23 | 1969-04-23 | |
| NO246169A NO120035B (no) | 1966-06-10 | 1969-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO120035B true NO120035B (no) | 1970-08-17 |
Family
ID=27484003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO246169A NO120035B (no) | 1966-06-10 | 1969-06-13 |
Country Status (1)
| Country | Link |
|---|---|
| NO (1) | NO120035B (no) |
-
1969
- 1969-06-13 NO NO246169A patent/NO120035B/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60121590T2 (de) | Pyrazolderivate | |
| DE69902634T2 (de) | Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien | |
| DE69013836T2 (de) | Benzimidazolverbindungen und deren Anwendung. | |
| DE3852565T2 (de) | Aryl-heteroaryl-karbinol-Derivate mit analgetischer Aktivität. | |
| DE69002341T2 (de) | Pyrimidinyl-piperazinyl-alkyl-azolyl-Derivate mit anxiolytischer und/oder beruhigender Wirksamkeit. | |
| DE69230225T2 (de) | Triazolylierte tertiäre aminverbindungen oder ihre salze | |
| EP0358595B1 (de) | N-Hetaryl-imidazolderivate | |
| DE1695139A1 (de) | Verfahren zur Herstellung von Imidazolderivaten | |
| DE69324141T2 (de) | Substituierte tertiäre amine und deren salze | |
| CH645100A5 (de) | Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung. | |
| JPS6345672B2 (no) | ||
| DE2638552A1 (de) | Thiazolinyl- oder thiazinylbenzimidazolester | |
| EP0050458A2 (en) | 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them | |
| EP0363796A1 (de) | Heterocyclische substituierte Alkoxycumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
| DE2411295A1 (de) | Substituierte benzimidazol-2-carbamatderivate, verfahren zu deren herstellung und diese enthaltende zusammensetzung | |
| EP0126296B1 (de) | Substituierte Phenyl-2-(1H)-pyrimidinone, Verfahren zu ihrer Herstellung und ihre Verwendung sowie diese Verbindungen enthaltende Zubereitungen | |
| EP0323799B1 (de) | Imidazolderivate II | |
| NO120035B (no) | ||
| DE1695189A1 (de) | Verfahren zur Herstellung von Imidazolderivaten | |
| DE1620018B2 (de) | 1-methyl-5-nitroimidazol-derivate, ihre salze mit saeuren, verfahren zu ihrer herstellung und antiparasitaere mittel | |
| US4808727A (en) | Imidazolium hydrogen carbonates | |
| DE68911944T2 (de) | Cardiotonische Alkanoyl- und Aroyloxazole. | |
| DE2348284A1 (de) | Neue imidazole und verfahren zu ihrer herstellung | |
| DD270906A1 (de) | Verfahren zur herstellung neuer imidazolderivate und deren verwendung als pharmazeutische mittel | |
| DE69207597T2 (de) | Lipoxygenase inhibierende tetrahydrobenzazepinderivate |